[go: up one dir, main page]

MX2024005626A - Composicion farmaceutica que comprende empagliflozina y sus usos. - Google Patents

Composicion farmaceutica que comprende empagliflozina y sus usos.

Info

Publication number
MX2024005626A
MX2024005626A MX2024005626A MX2024005626A MX2024005626A MX 2024005626 A MX2024005626 A MX 2024005626A MX 2024005626 A MX2024005626 A MX 2024005626A MX 2024005626 A MX2024005626 A MX 2024005626A MX 2024005626 A MX2024005626 A MX 2024005626A
Authority
MX
Mexico
Prior art keywords
empagliflozin
pharmaceutical composition
heart failure
hospitalization
preserved
Prior art date
Application number
MX2024005626A
Other languages
English (en)
Inventor
Uli Broedl
Afshin Salsali
Hans- Juergen WOERLE
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2024005626A publication Critical patent/MX2024005626A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos para prevenir o tratar insuficiencia cardíaca crónica o aguda y para reducir el riesgo de muerte cardiovascular, hospitalización por insuficiencia cardíaca y otras afecciones en pacientes con fracción de eyección reducida o conservada mediante la administración de empagliflozina al paciente.
MX2024005626A 2016-03-16 2018-09-13 Composicion farmaceutica que comprende empagliflozina y sus usos. MX2024005626A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309008P 2016-03-16 2016-03-16
US201662420062P 2016-11-10 2016-11-10

Publications (1)

Publication Number Publication Date
MX2024005626A true MX2024005626A (es) 2024-05-24

Family

ID=58267120

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2018011088A MX2018011088A (es) 2016-03-16 2017-03-13 Composicion farmaceutica que comprende empagliflozina y sus usos.
MX2024005626A MX2024005626A (es) 2016-03-16 2018-09-13 Composicion farmaceutica que comprende empagliflozina y sus usos.
MX2022008491A MX2022008491A (es) 2016-03-16 2018-09-13 Composicion farmaceutica que comprende empagliflozina y sus usos.
MX2021010329A MX2021010329A (es) 2016-03-16 2018-09-13 Composicion farmaceutica que comprende empagliflozina y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018011088A MX2018011088A (es) 2016-03-16 2017-03-13 Composicion farmaceutica que comprende empagliflozina y sus usos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022008491A MX2022008491A (es) 2016-03-16 2018-09-13 Composicion farmaceutica que comprende empagliflozina y sus usos.
MX2021010329A MX2021010329A (es) 2016-03-16 2018-09-13 Composicion farmaceutica que comprende empagliflozina y sus usos.

Country Status (13)

Country Link
US (6) US20170266152A1 (es)
EP (1) EP3429595A1 (es)
JP (4) JP7161405B2 (es)
KR (6) KR20180122004A (es)
CN (4) CN109069525A (es)
AU (3) AU2017233889B2 (es)
BR (1) BR112018016001A2 (es)
CA (1) CA3017992A1 (es)
CL (1) CL2018002532A1 (es)
MA (1) MA43709A (es)
MX (4) MX2018011088A (es)
PH (2) PH12021552046A1 (es)
WO (1) WO2017157816A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
CN102307577A (zh) 2009-02-13 2012-01-04 贝林格尔.英格海姆国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
BRPI1013640A2 (pt) 2009-02-13 2019-09-24 Boehringer Ingelheim International Gmbh composicao farmaceutica, metodos para o tratamento e usos dos mesmos
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE058731T2 (hu) 2013-04-18 2022-09-28 Boehringer Ingelheim Int Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai
CN109922813A (zh) 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
MX2020003243A (es) * 2017-10-02 2020-09-18 Poxel Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
ES2929994T3 (es) 2018-06-06 2022-12-05 Poxel Sa Métodos de tratamiento de sujetos que padecen diabetes con enfermedad renal crónica
WO2019238647A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
AU2019304032B2 (en) * 2018-07-19 2021-12-09 Astrazeneca Ab Methods of treating HFpEF employing dapagliflozin and compositions comprising the same
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN109846898A (zh) * 2019-02-01 2019-06-07 同济大学 恩格列净在制备治疗和/或预防心肌梗死的药物中的应用
IT201900006624A1 (it) * 2019-05-08 2020-11-08 Moret Giannino Combinazione di canrenone e enalapril per uso nella terapia dei pazienti diabetici.
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
MX2020005388A (es) * 2019-08-30 2022-10-25 Astrazeneca Ab Uso de composiciones farmacéuticas que comprenden dapagliflozina e inhibidores de sglt2.
WO2021049612A1 (ja) * 2019-09-13 2021-03-18 国立大学法人富山大学 急性心不全における体液貯留改善薬
AU2021222297B2 (en) * 2020-02-17 2026-01-22 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
EP4376829A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
JP7396579B2 (ja) * 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
CN121218995A (zh) 2023-05-24 2025-12-26 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及匹莫苯丹和/或替米沙坦的非人类哺乳动物中心脏疾病的组合治疗和/或预防

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723309B2 (en) * 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
JP5736377B2 (ja) * 2009-09-30 2015-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １−クロロ−４−（β−Ｄ−グルコピラノス−１−イル）−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）ベンジル］ベンゼンの結晶形の調製方法
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9192617B2 (en) * 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) * 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) * 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
HUE058731T2 (hu) * 2013-04-18 2022-09-28 Boehringer Ingelheim Int Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai

Also Published As

Publication number Publication date
KR20250161667A (ko) 2025-11-17
CN118903166A (zh) 2024-11-08
MA43709A (fr) 2018-11-28
CN109069525A (zh) 2018-12-21
JP2024083347A (ja) 2024-06-21
KR20230028565A (ko) 2023-02-28
BR112018016001A2 (en) 2018-12-18
US20220211659A1 (en) 2022-07-07
AU2022246392A1 (en) 2022-10-27
KR20230028568A (ko) 2023-02-28
AU2017233889A1 (en) 2018-08-09
PH12021552046A1 (en) 2022-06-27
PH12018501969A1 (en) 2019-06-17
MX2022008491A (es) 2022-08-02
US20180318251A1 (en) 2018-11-08
JP7454531B2 (ja) 2024-03-22
CN118286237A (zh) 2024-07-05
JP2021181461A (ja) 2021-11-25
KR20240095321A (ko) 2024-06-25
MX2021010329A (es) 2021-10-13
WO2017157816A1 (en) 2017-09-21
AU2017233889B2 (en) 2022-07-07
CL2018002532A1 (es) 2019-01-04
JP2019508453A (ja) 2019-03-28
US20210059974A1 (en) 2021-03-04
AU2024216447A1 (en) 2024-09-19
US20190350894A1 (en) 2019-11-21
CN118286238A (zh) 2024-07-05
JP7161405B2 (ja) 2022-10-26
JP2023001136A (ja) 2023-01-04
CA3017992A1 (en) 2017-09-21
AU2022246392B2 (en) 2024-09-19
US20250073200A1 (en) 2025-03-06
MX2018011088A (es) 2018-11-22
KR20180122004A (ko) 2018-11-09
US20170266152A1 (en) 2017-09-21
KR20230111262A (ko) 2023-07-25
EP3429595A1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
PH12020500352A1 (en) Therapeutic uses of empagliflozin
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX378422B (es) Uso de empagliflozina para el tratamiento de trastornos metabòlicos, la prevenciòn, y para la reducciòn del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX394909B (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
EP4570314A3 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
AU2014375637A1 (en) Formula of neuregulin preparation
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
NZ754706A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
BR112017015840A2 (pt) método de tratamento ou prevenção de eventos aterotrombóticos em pacientes com histórico de infarto do miocárdio
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
MX2017003217A (es) Tratamiento del cancer con el inhibidor de la alfa-amilasa en los animales de compañía.
MD20180049A2 (ro) Compoziţie farmaceutică
WO2017010673A3 (ko) 혈관누수 증후군의 예방 또는 치료용 조성물
WO2019078634A3 (ko) Ptp4a1 단백질을 포함하는 인슐린 저항성 또는 지방간의 예방 또는 치료용 약학적 조성물
MX382374B (es) Nutrición infantil que proporciona beneficios metabólicos.
EA201892048A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин, и ее применения
MX2014010749A (es) Composicion ginecologica para tratar la vestibulitis vulvar.
MX2017011838A (es) Composiciones y metodos para tratar carcinoma hepatocelular.
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения